These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16278478)

  • 21. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural history and treatment of bone complications in prostate cancer.
    Saad F; Clarke N; Colombel M
    Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
    Reddi AH; Roodman D; Freeman C; Mohla S
    J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions.
    Yonou H; Ochiai A; Goya M; Kanomata N; Hokama S; Morozumi M; Sugaya K; Hatano T; Ogawa Y
    Prostate; 2004 Mar; 58(4):406-13. PubMed ID: 14968441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone and prostate cancer cell interactions in metastatic prostate cancer.
    Vela I; Gregory L; Gardiner EM; Clements JA; Nicol DL
    BJU Int; 2007 Apr; 99(4):735-42. PubMed ID: 17166237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis.
    Bonfil RD; Chinni S; Fridman R; Kim HR; Cher ML
    Urol Oncol; 2007; 25(5):407-11. PubMed ID: 17826661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bi-directional interactions of prostate cancer cells and bone marrow endothelial cells in three-dimensional culture.
    Barrett JM; Mangold KA; Jilling T; Kaul KL
    Prostate; 2005 Jun; 64(1):75-82. PubMed ID: 15651029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When prostate cancer meets bone: control by wnts.
    Emami KH; Corey E
    Cancer Lett; 2007 Aug; 253(2):170-9. PubMed ID: 17462819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.
    Chirgwin JM; Guise TA
    J Cell Biochem; 2007 Dec; 102(6):1333-42. PubMed ID: 17907152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The bone microenvironment in metastasis; what is special about bone?
    Bussard KM; Gay CV; Mastro AM
    Cancer Metastasis Rev; 2008 Mar; 27(1):41-55. PubMed ID: 18071636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
    BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of tumor microenvironment in prostate cancer bone metastasis.
    Morrissey C; Vessella RL
    J Cell Biochem; 2007 Jul; 101(4):873-86. PubMed ID: 17387734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells.
    Haq M; Goltzman D; Tremblay G; Brodt P
    Cancer Res; 1992 Sep; 52(17):4613-9. PubMed ID: 1511429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone-directed treatments for prostate cancer.
    Saad F
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a unique set of genes altered during cell-cell contact in an in vitro model of prostate cancer bone metastasis.
    Wang J; Levenson AS; Satcher RL
    Int J Mol Med; 2006 May; 17(5):849-56. PubMed ID: 16596270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multi-targeted approach to treating bone metastases.
    Camacho DF; Pienta KJ
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):545-53. PubMed ID: 24390423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.